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Background: Obesity remains a serious but preventable challenge of our time, and it has 
been linked to many comorbidities. This study uses body mass index (BMI) as a measure of 
obesity to investigate the relationship between low and high BMI and total cancer 
incidence, as well as some common specific cancers. These relationships were explored in 
relatively young subjects who may lose more life years to cancer. 
Method: A population-based cohort study was carried out using the third Tromsø survey of 
1986-87 (Tromsø 3) with the Norwegian Cancer Registry (up to December 2010). The 
cohorts, which were year of birth based, were aged 20-61 years (men) and 20-56 years 
(women) in 1986. A total of 19,943 subjects (10,219 men and 9,724 women) were followed 
up for a mean period of 22.41 years. During the follow-up period, a total of 2,248 incident 
cancers were identified with 1,252 (55.7%) in men, and 996 (44.3%) in women. The 
relationship of the subjects’ BMI to the cancer incidence was explored using Cox 
proportional hazards regression to compute the hazard ratios (HR). In most of the analyses, 
subjects with BMI 20.0-24.9 kg/m2 were the reference category. 
Results: In men, a U-shaped relationship between BMI and total cancer incidence was 
observed, with men of BMI 20.0-24.9 kg/m2 having the lowest risk of cancer occurrence 
(BMI < 20.0 kg/m2: HR=1.41 [95% CI: 1.03-1.93]; BMI ≥ 30.0 kg/m2: HR=1.30 [95% CI:  1.03-
1.63]). Unlike in men, there was essentially no relationship between BMI and the total 
cancer incidence observed in women. BMI appeared indifferent to prostate cancer risk, 
while BMI < 20.0 kg/m2 and ≥ 30.0 kg/m2 were associated with increased risk of lung cancer. 
In men, BMI may be a strong risk factor in colon cancer, with BMI < 25.0 kg/m2 having the 
lowest risk (BMI 25.0-29.9 kg/m2: HR=1.81 [95% CI: 1.19-2.74]; BMI ≥ 30.0 kg/m2: HR=1.83 
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[95% CI: 0.88-4.07]). In women, a null relationship was observed. However, when the 
women cohort were stratified into 2 by their mean age at baseline, 36 years, a relatively 
strong positive linear relationship was found between BMI and colon cancer risk in those 
younger than 36 years at the study baseline (BMI 25.0-29.9 kg/m2: HR=2.09 [95% CI=0.57-
7.58]; BMI ≥ 30.0 kg/m2: HR=5.26 [95% CI: 1.15-24.06]). In men, a positive linear relationship 
was found between BMI and the risk of colorectal cancer (BMI < 20.0 kg/m2: HR=0.67 [95% 
CI: 0.16-2.74]; BMI ≥ 30.0 kg/m2: HR=1.81 [95% CI=1.01-3.22]). No marked fluctuation in the 
risk of colorectal cancer was observed in women. 
Conclusion: Low and high BMI have impacts on the total cancer risk in the relatively young 
and the middle aged population, as well as the risk of some of the other specific cancers 
studied. Therefore, any public health policies directed at reducing cancer incidents should 
address both ends of the BMI spectrum in the community. 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
Obesity is one of the most serious and preventable public health challenges of the 21st 
century (1). It is a condition in which there is excess accumulation of body fat. The World 
Health Organization (WHO) defined obesity as abnormal or excessive fat accumulation that 
may impair health (2), and this is traditionally regarded as a weight of at least 20% above 
the recommended for a specific height (3). 
In simple terms, obesity occurs as a result of intake of more calories through diet than is 
burnt through active living or physical activities. This caloric imbalance may be caused 
singularly or in combination with genetic, environmental or and behavioral factors (1, 2). 
Some medications and disease conditions are also known to cause weight gain (4). In 2013, 
the American Medical Association classified obesity as a disease (5). 
There are some accurate methods of measuring obesity, such as magnetic resonance 
imaging (MRI), computerized tomography (CT), dual-energy X-ray absorptiometry, 
underwater weighing, air-displacement plethysmography, and bioelectric impedance 
analysis. However, these measurement methods are not suitable for large population 
studies (6). There is no absolutely flawless population-based method of measuring obesity, 
nevertheless, the most commonly used methods are anthropometric, and are body mass 
index (BMI), waist circumference, waist-to-hip ratio, waist-to-height ratio and skinfold 
thickness. This research work shall make use of the BMI method. This provides a very useful 
population-level measure of obesity because it is the same for both male and female adults 
2 
 
of all ages (2, 6). BMI is calculated by dividing the weight (in kilograms) by the square of the 
height (in metres) of the individual. 
1.2 How common is obesity? 
The prevalence of obesity is reportedly rising rapidly throughout the world, and has been 
described as one of the fastest developing global public health challenges of the present day 
(6, 7). 
In the United States, the National Health and Nutrition Examination Survey (NHANES) 
carried out a study between 1988 and 1994 and revealed that about 56 per cent of adult 
age 20 and above were either overweight or obese. By 2007-2008, about 68 per cent of 
same group were overweight or obese (8). In a population-based study carried out in 
Tromsø, Norway, the BMI of the participants was found to have increased during a 15 to 20 
year follow-up (1974-1994) in all the examined birth cohorts of the population (9). This 
same trend was also found in another study, the Nord-Trøndelag Health Study (HUNT Study) 
where a large representative of adult Norwegian population was followed over 22 years 
(10). Findings from the HUNT Study indicate rising prevalence of obesity in Norway, as do 
unpublished recent results from the Tromsø Study shown (10, 11). 
In 2008, the WHO estimated over 1.4 million adults age 20 and above to be overweight, out 
of which about 500 million were obese. This means more than 10% of the world’s adult 
population was obese (2). And going by the WHO projection, it is estimated that by the year 
2015, about 2.3 million adults will be overweight of which more than 700 million will be 
obese (6). It follows then that any disease conditions associated with obesity will most likely 
increase just as those who are obese increase in number. 
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1.3 Cancer and the link to obesity 
WHO describes cancer as an uncontrolled growth and spread of cells which can affect 
almost any parts of the body (12).  Cancer is one of the leading causes of death worldwide. 
In 2012, it accounted for about 8.2 million deaths globally (12, 13). The common types of 
cancer differ from males to females, and may also differ from one part of the world to 
another. The 5 leading behavior and dietary risks account for about 30% of cancer deaths, 
and these risks, as cited by the WHO, are: tobacco use, obesity, low fruit and vegetable 
intake, lack of physical activity, and alcohol use (12). Obesity is second only to smoking as an 
avoidable risk of cancer death. Sadly, it is projected that the annual cancer occurrence will 
increase from about 14 million in 2012 to about 22 million within the next 20 years (12, 13), 
and this may not be unconnected with the epidemic rise of overweight and obese 
population in the world. 
The association between obesity and some disease conditions such as heart diseases and 
diabetes have consistently been demonstrated and often with good public awareness (14, 
15). However, it appears there is still relatively insufficient public and political acceptance 
and precise perception of the ties between obesity and cancer. 
This may be partly due to the fact that most studies addressing the issue of the association 
between obesity and cancer usually make use of heterogeneous population including many 
cities and diverse people of different cultural values, societal mores, and urbanity. Such is 
the widely cited prospective cohort study conducted in the United States by Calle et al. 
(2003) whereby participants were from all 50 states, the District of Columbia, and Puerto 
Rico (16). While this may be of statistical advantage, individuals and each city may not fully 
identify with the findings and conclusions. 
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On the other hand, a prospective cohort study involving only a city and followed up for 
decades may be relatively easily brought to that specific public (or city’s) awareness. The 
findings may also be easy to identify with, and the population-based desired associated 
behavioral or dietary changes effected. This is the ultimate goal of public health service - to 
effect positive changes in the community. Such special opportunity is offered by the data of 
the Tromsø study when merged with the Norwegian Cancer Registry. 
1.4 Cancer and the link to low weight 
In most Western populations, underweight is much less prevalent than obesity, and most 
studies have concentrated their investigations on the relationship between obesity and 
cancer risk. Nevertheless, there are findings that are strongly suggestive that underweight 
may be a cancer risk factor in some specific organs or sites (17, 18). 
1.5 The Tromsø Study 
The Tromsø Study originally started in 1974 in an attempt to fight the high mortality of 
cardiovascular diseases in Norway (19). The first survey was denoted as Tromsø 1, and since 
then, there have been 5 other Tromsø study surveys conducted at intervals of 5-8 years, 
representing Tromsø 1-6. 
This research work shall make use of Tromsø 3 survey initiated in 1986-87 because of the 
available dataset therein and the corresponding length of follow-up. When this is merged 
with the matching Cancer Registry, all other needed information shall be captured. 
1.6 Purpose of the Study 
There is a strong relationship between age and cancer risk, and the impact (in terms of 
relative risk) of most other risk factors tends to attenuate with age. Cancer at a relatively 
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early age may be much more important than in the old age because of more years of life 
that may be lost to cancer. Therefore, it is of interest to study the BMI-cancer relationship in 
the relatively young and middle aged people as we intend to do in this study. 
Thus, the overall purpose of this study is to explore the relationship between BMI and 
cancer in the relatively young and middle-aged adults in Tromsø municipality, Norway. This 
study is envisaged to expand the literature and add to the body of knowledge in this area. 
This work is also expected to serve as an important material for other similar cities in 
Norway and Europe. 
1.7 Research Hypotheses 
1. Low and high body mass indexes increase the risk of total cancer incidence. 
2. Low and high body mass indexes increase the risk of incidence of some common cancers. 
1.8 Research Questions 
The primary aim of this study was to answer the following questions: 
1. What is the relationship of BMI to the total cancer incidence? 
2. What is the relationship of BMI to the most common incident cancers in Tromsø? 
 
This research work shall follow a quantitative research approach with a prospective study 
methodology. The needed dataset shall be obtained from the Data and Publication 







1.9 Outline of the Study 
This thesis is organized in six chapters: 
Chapter 1 is the introduction to the study. It gives the foretaste to the study. 
Chapter 2 presents the literature review, highlighting relevant previous researches 
conducted in the area of the current study and the pertinent theoretical or biological 
framework. 
Chapter 3 describes the details of the methodology guiding the study. 
Chapter 4 contains the key findings of the study. 
Chapter 5 discusses these key findings, their scientific consonance with the previous 
researches, theoretical framework, and clinical or public health relevance. 










CHAPTER 2: LITERATURE REVIEW 
2.1 Database search 
The literature was first searched in October 2013 (and updated till June 2014) to find 
previous relevant studies conducted in the area of the current study. A broad initial search 
was conducted in Cochrane, PubMed, Thomson ISI’s Web of Science, and Google Scholar. 
The keywords and or Medical Subject Heading (MeSH) terms used were: obesity, 
overweight, excess body weight, body mass index, and Cancer. The search was later focused 
on some specific cancer sites such as prostate, lungs, colon and rectum (breast cancer was 
not a special focus for reasons given on page 13). The references of the relevant articles so 
found were further searched to identify more articles related to the study subject matter. 
2.2 Obesity and cancer 
The awareness of the health problems associated with obesity has long been known to man. 
This was portrayed by Hippocrates when he reportedly wrote that “Corpulence is not only a 
disease itself, but the harbinger of others” (20, 21), thereby acknowledging that obesity 
leads to other comorbidities. 
There is large amount of scientific evidence from the laboratory that fat animals are more 
likely to develop cancer than the lean ones. When this happens, the cancers grow large, 
faster and spread more quickly in the fat experimental animals (22). This same corollary has 
been observed in humans by different studies. One of such was a study conducted by Daling 
et al (2001) on invasive ductal breast cancer in 1,177 women. They found that those in the 
uppermost range of excess body weight developed cancers of higher histological grade and 
relatively larger cancer size compared with normal weight individuals (23). 
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In the European Union, Bergstrom et al (2001) estimated that about 5% of all incident 
cancers were due to obesity (24), with about 3.5% in males and 6.5% in females. This 
translates to approximately 72,000 additional cases each year (25). In a more recent article 
by Wolin, Carson and Colditz (2010), obesity was said to be responsible for about 20% of all 
cancers in humans (26). However, excess weight does not increase the risk of cancer by the 
same amounts or measures in different tissues (26-30). These measures (or associations) 
may also be sex-specific over a range of cancers (28). Calle et al (2003) found a dose-
response relationship between excess body weight as measured by BMI and all cancers 
combined, and this relationship differed by gender (16). They used BMI of 18.5-24.9 kg/m2 
as the reference category, and for women of BMI 25.0-29.9 kg/m2, 30.0-34.9 kg/m2, 35.0-
39.9 kg/m2, and 40.0 kg/m2 and above, the risks of developing cancer were 8%, 23%, 32%, 
and 62% higher, respectively. For men, only BMI 30.0 kg/m2 and above carried increased 
risk of cancer. For BMI 30.0-34.9 kg/m2, 35.0-39.9 kg/m2, and 40.0 kg/m2and above, the 
risks of developing cancer were 9%, 20%, and 52% higher, respectively (16). 
There is also ethnic variations and affinity in obesity-cancer risk. In a meta-analysis 
conducted by Renehan et al (2008), they found a particularly strong association between 
increased BMI and breast cancer in the Asia-Pacific women population (28). The African 
American also show relative susceptibility to cancer compared to the Hispanic who are 
somewhat protected (31). 
2.3 Obesity and Some Specific Cancers 
The International Agency for Research on Cancer (IARC) in 2002 concluded that there was 
ample scientific evidence linking obesity and some specific cancers. These cancers include 
that of the colon, post-menopausal breast, endometrial, kidney and esophageal (32). About 
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11% of colon cancer was ascribed to obesity, while it was 9% in post-menopausal breast 
cancer. About 39% of endometrial cancer, 25% of kidney cancer, and 37% of esophageal 
cancer, were attributed to excess body weight (32). 
Following the prospective study of Calle et al (2003), more obesity-linked cancers were 
observed and added to the list. They were: liver, pancreatic, non-Hodgkin lymphoma, and 
myeloma (16, 33). Some of these cancers are strongly related to obesity with apparently 
convincing evidence while others are only weakly linked with probable evidence, and also 
with gender influence (31, 33). 
2.4 Pathophysiological and biological framework linking obesity to cancer 
In the attempt to further ascertain the link between excess body weight and cancer risks, 
there have been many studies directed at understanding the possible mechanisms involved 
in the linkage. A detailed summary of all the possible mechanisms is beyond the scope of 
this thesis. Howbeit, these mechanisms linking excess body weight and cancer risk are yet to 
be completely understood (30). Nevertheless, the three most studied mechanisms or 
postulations shall be discussed briefly. 
2.4.1 Insulin and insulin-like growth factors (IGFs) 
It has been established that excess body weight is associated with reduced insulin 
sensitivity. In other words, obesity correlates positively with insulin resistance (31). This 
situation triggers a compensatory stimulation of the pancreas for more insulin which usually 
leads to persistent hyper-insulinaemia (30, 31, 33). 
The “insulin-cancer hypothesis” proposed that persistent hyper-insulinaemia decreases the 
production of insulin-like growth factors binding proteins -1 and -2 (IGFBP-1 and IGFBP-2). 
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These IGFBPs are supposed to bind with insulin-like growth factors -1 and -2 (IGF -1 and -2) 
and thus inhibit the actions of the growth factors (IGF). When there is decreased production 
of IGFBPs it results into bioavailability of free IGF. IGF-1 attributably changes the cellular 
environment in favour of cancer development (27, 30, 31, 33-36) (Figure 1). The attributes 
of IGF favouring cancer development include, but not limited to: mitogenic (induce cell 
division); anti-apoptotic (prevent necessary or programmed cell death); pro-angiogenic 
(support formation of new blood vessels); stimulate cancer-related lymphangiogenesis; 
increase cell migration; and enhanced the effectiveness of other cell growth stimulants such 
as oestrogens (30, 31, 34). 




…reduced insulin sensitivity           Target cell 
…compensatory insulin production 
…decrease production of IGFBP 
 
Studies and subsequent meta-analysis have demonstrated that the total circulatory IGF 
consistently associate positively with increased risk of colorectal (37), prostate (38) and pre-
menopausal breast cancer (30, 33, 34). 
In spite of all these, the insulin-IGF hypothesis has 2 major fundamental discrepancies (30). 
The blood levels of total circulating IGF increase linearly with increasing BMI up to about 
BMI 27 kg/m2 and subsequent decrease with increasing BMI (36). Secondly, the total IGF 
Excess body 
weight 





of free IGF 






levels of obese people who intentionally lose weight tend to increase in value despite their 
decreasing weight (30). These are key inconsistencies in this biological framework. 
2.4.2 Sex Hormones 
Some cancers, such as endometrial, uterine, ovarian, breast and prostate cancers are 
considered to be hormone dependent (33). There are evidences that obesity affects the 
production of the sex hormones which have been implicated in the development of cancer 
(33). These endogenous hormones include oestrogens (such as oestradiol), androgens (such 
as testosterone) and progestogens (such as progesterone). The increased breast cancer risk 
in obese post-menopausal women may be explained by increased aromatase enzyme 
activity in the adipose tissue resulting in faster conversion of androgenic precursors to 
oestradiol (34). There are consistent indications that increase circulating oestrogens 
increase the risk of breast cancer in women after menopause (34). The implicative attributes 
of oestrogens in causing breast cancer development may be via increasing DNA damage, 
genetic instability and mutation (34). However, Renehan et al (2008) posit that oestrogens’ 
proliferative effects may be the most important (34). 
Androgens levels (such as testosterone) are inversely related to BMI in men while it directly 
correlated in women (39, 40). Elevated levels of androgens have been associated with both 
pre and post-menopausal breast and endometrial cancers, thus linking excess body weight 
and cancers (31). 
2.4.3 Adipokines 
Adipokines are polypeptide hormones derived from adipose tissue (or adipocytes). There 
are more than 50 types of adipokines, but the most well-known and studied is leptin (33, 
34). This may be because it is one of the most abundantly produced adipokines in the body, 
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and its levels in the circulation correlate directly with BMI (34). Vona-Davis and Rose (2007) 
observed that leptin may be mitogenic, pro-angiogenic, pro-inflammatory, and anti-
apoptotic (41). Some studies have demonstrated associations between serum leptin and 
colorectal cancer, breast cancers, but the association with prostate cancer has been 
inconsistent (34). 
2.5 Pathophysiological and biological framework linking underweight to cancer 
The biologic mechanism and evidence linking underweight to increased cancer risk is less 
known (17). Nevertheless, central to the underweight-cancer hypothesis is the oxidative 
DNA stress, which has been implicated in the initiation and promotion of carcinogenesis 
(42). Decreasing levels of BMI are associated with significantly increased levels of DNA 
oxidative damage. The oxidative damage is measured by 8-hydroxydeoxyguanosine, which is 
a biomarker of oxidative injury (42). Likewise, lower BMI has been shown to correlate with 
increased risk of lung cancer (18). 
The BMI-related cancers are diverse and apparently there is no single mechanism or 
pathway to explain all (34). Many studies have been conducted in the area of obesity and 
cancer, but more are still required because there are still many inconsistencies and 
knowledge gaps. This was recently reiterated by Boeing (2013) who suggested that analyses 




CHAPTER 3: RESEARCH METHODOLOGY 
3.1 Ethical Consideration and Permission 
Application was made for the data of the 3rd Tromsø Study of 1986-87 (hereafter referred to 
as Tromsø 3). Access to the relevant data file with the required variables was granted by the 
Data & Publication Committee of the Department of Community Medicine of UiT-The Arctic 
University of Norway. The research study was found to be covered by the existing approvals 
and concessions from the Regional Committee for Medical Research Ethics (REK) and the 
Norwegian Data Inspectorate. However, we were, unfortunately restrained by the Data & 
Publication Committee from using the given dataset for the study of breast cancer to 
prevent conflict of interest with another larger on-going research project. 
The national 11-digit personal identification number enables thorough follow-up of 
participants concerning cancer, death, emigration and so on, by linkage to the official 
national registries, and in this case cancer register. The data quality of the Norwegian 
Cancer Registry is of high standard because it is made compulsory by law (19, 44). 
3.2 The Third Survey of the Tromsø Study - Tromsø 3 
This research work made use of Tromsø 3 which took place following the successful conduct 
of the first and the second Tromsø survey. Tromsø 3 was initiated in 1986. It was a 
prospective population-based cohort study in the municipality of Tromsø. Tromsø is 
geographically located about 350 kilometres north of the Arctic Circle, and it is the largest 
city in the Northern Norway with population of about 67,000 inhabitants. The population 
studied is almost exclusively Caucasian, and the enrolment was based on the official 
population registry of the Tromsø municipality. Through this, the residents were invited on 
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the basis of their year of birth at the time of the survey (19). All men aged 20-61 years (born 
1925-1966) and all women aged 20-56 years (born 1930-1966) were invited. An additional 
small numbers of individuals younger and older than the above-mentioned cohorts were 
also invited. These individuals were not, however, random samples of the population and 
were therefore not included in the analytical sample which this present analyses are based 
on. Only men were invited for the birth cohort born in 1925-29 (Figure 2). This was 
reportedly because the Tromsø Study was originally aimed at middle-aged men and this 
group of men was being followed from the first survey of the Tromsø Study (Tromsø 1) in 
1974 (19). 
Figure 2 - The Tromsø Study: Invitation by birth cohort and attained age in Tromsø 3 




 Men only 
 Invitation of total birth cohort of men and women 
 10% of total birth cohort and offspring of high risk men  
who took part in a family intervention trial after Tromsø 2. 
            (Adapted from Jacobsen et al., 2012 (19)) 
 
Personal invitation which included information about the survey, the examination, and a 
questionnaire were sent to the potential participants by mail about a couple of week before 
the proposed date of appointment for each person. However, each individual could attend 
at any other more convenient time within the lifespan of the study which was about one 





21,826 attended 29,026 invited 
Born 1930-66, 
aged 20-56 years 
Born 1967-74, 
aged 12-19 years 
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3.3 Study Population 
The men and women in this study were selected from the 21,826 who attended Tromsø 3 
survey in 1986-87. 93 participants refused their data from being used for research. Thus, the 
remaining 21,733 participants were subjected to inclusion and exclusion criteria. 
3.4 Inclusion and Exclusion Criteria 
Men aged between 20 and 61 years, and women aged between 20 and 56 years were 
included in the analysis, as all subjects in these age groups were invited. This age bracket 
excluded 550 men and 673 women leaving us with 20,510 attending subjects. We excluded 
subjects with missing value for BMI or unreliable BMI (such as in denial of height or weight 
measurement, pregnancy, disability, measured with shoes, limping or bent individuals). This 
criterion excluded 75 men and 288 women. Also excluded were those who had been 
diagnosed with cancer before they attended Tromsø 3 survey (prevalent cancer cases). This 
criterion excluded 204 subjects of which 83 were men and 121 were women. The eligible 
participants for the current analysis included 10,219 men and 9,724 women (Figure 3). 
Figure 3 - Application of inclusion and exclusion criteria and study population 
 
          
            
FILTERS: Ag                                                                                                                                                                                                                                       
1. Age (excluding men outside 20-61 years, & women outside 20-56 years) 
 
 
2. BMI (excluding unreliable values)  
 
 
















93 declined their 
data from being 
used for research 
550 men & 673 
women excluded 
75 men & 288 
women excluded 
83 men & 121 
women excluded 
MEN (%) WOMEN (%) 
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3.5 Body Mass Index 
The body mass index (BMI) which is a measure of adiposity, was categorized into: less than 
20.0 kg/m2 (“underweight”, “low-weight” or “thin”); 20.0 to 24.9 kg/m2 (“healthy”, 
“normal”, “recommended” or “acceptable” weight); 25.0 to 29.9 kg/m2 (“overweight”); and 
30.0 kg/m2 and above (“obese”). These categories are exactly the same as used in some 
previous studies (9), and closely similar to those proposed by the WHO (6).  
In all the analyses, BMI category of 20.0 to 24.9 kg/m2 was made the reference group. For 
the analyses of some cancers in specific sites, a slight modification was made by combining 
the lower 2 categories of the BMI. This was done because of the limited numbers of events. 
3.6 Cancer Endpoints 
The end points in the analyses were cancers from all sites, following the International 
Classification of Diseases, 10th Revision (ICD-10) and as grouped together by the Norwegian 
Cancer Registry. The endpoint was considered to occur if the subject had tumor degree of 
malignance and reliability of tumor origin equals to 3 and above, on a scale of 1 to 5. Only 
the first cancer cases were considered. We assumed that the second cancer cases may be 
influenced by the first and may have profound effect on the BMI. During the follow-up 
period, a total of 2,248 incident cancers were identified (1,252 in men and 996 in women). 
Analyses were run for all cancers combined, separately for the 2 genders, and then for the 
first four commonest cancer sites (breast cancer was left out to prevent conflict of interest 
of another on-going research project (see page 13)). 
3.7 Follow-up 
Follow-up was from the date the participants attended the survey (in 1986-1987) to the first 
of the following dates: date of diagnosis of cancer (2,248 incident cancers); death (2,503 
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deaths); emigration from Norway (331 emigrants); or end of follow-up (December 31, 2010). 
End of follow-up was end of 2010 as this was the latest available data from the Cancer 
Registry of Norway as at the time of writing this thesis. 
3.8 Information on the Covariates  
The 5 potential confounders taken into consideration were age (in single years); smoking 
status (current smoker; ex-smoker; and never smoker); physical activity (lasting at least 20 
minutes into: rarely or never, weekly, several times a week, and daily); alcohol consumption 
(yes or no); and level of education (less than high school; high school; bachelor degree; and 
master degree and above). Only the first 2 were used in the final analyses (see section 3.9). 
3.9 Statistical Analysis 
The software package IBM SPSS Statistics for Windows (Version 21.0. Armonk NY: IBM Corp) 
was used for all analyses. Men and women were analyzed separately, but together when 
necessary. The covariates were tested for normal distribution by visual inspection of the 
distribution curves. Frequencies and cross-tabulation were made for the categorical data.  
The crude incidence rate of all cancers combined and some specific cancer sites in men and 
women were estimated as the number of cases per 100,000 person-years. The persons-time 
(or men- and women-years) were calculated as the sum of cancer-free follow-up time (in 
years). Cox proportional hazards regression modeling was used to compute the hazard ratio. 
The hazard ratio was assumed to be very close to the relative risk, and thus used 
interchangeably. P-values less than 0.05 were considered statistically significant. We 
adjusted for age and smoking status (current smoker, ex-smoker or never smoker). Variables 
such as physical activity, alcohol consumption, and levels of education were initially 
adjusted for in the analyses. However, adjusting for these 3 variables had little or no impact 
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on the results with regard to the relationship between BMI and cancer incidence. This was 
true for total cancer incidence as well as the specific cancer sites considered. Hence they 
were not included in the final statistical model presented here. Furthermore, when 
interactions terms BMI and age, BMI and smoking, as well as smoking and age were 
included in the model for total cancer incidence, there were no significant interaction for 
the two former interaction terms (including information about BMI), but the interaction 
term smoking and age was statistically significant (p = 0.04 in both men and women). 
However, including this interaction term in the model did not change the point estimates for 
the effect of BMI more than marginally. Thus, we did not include these interaction terms in 
the model presented. 
A test of linear trend in risk of cancer according to BMI categories was done by scoring the 
BMI categories 1 to 4 and entering the scores as continuous term in the Cox regression 
model. Likewise, the p-value for non-linear relationship was computed by including a second 
order term in the model. 
3.10 Assumptions of proportional hazards in models 
The proportional hazards model assumes that the hazard under investigation is consistent 
and do not vary differently over time. This was assessed visually by checking the log minus 
log plots made for the different cancer types. The curves in each plot were not perfectly, but 
approximately parallel, except in few plots where minimal crossings were observed towards 
the ends of the curves. In addition, the plots of the residuals (Schoenfeld residuals) were 
horizontal and close to zero, meaning that the assumption of proportional hazards was true.  
The results of all cancers combined and the specific cancer sites analyzed were presented 
based on the study population. 
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CHAPTER 4: RESULTS 
4.1 Baseline characteristics 
Following the application of inclusion and exclusion criteria (see Methodology section and 
Figure 3), the eligible study population was 19,943 subjects. 10,219 (51.2%) of them were 
men while 9,724 (48.8%) were women. 
The mean age of men in the study at the start of the follow-up was 38.61 years, while 20 
and 61 years were, by design, the minimum and maximum age, respectively. The mean age 
of women was 36.31 years, and 20 and 56 years were, by design, the minimum and 
maximum age, respectively. The men had a mean BMI of 24.61 kg/m2, while 14.50 kg/m2 
and 47.30 kg/m2 were the minimum and maximum BMI respectively. The women had a 
mean BMI of 23.09 kg/m2, and 13.30 kg/m2 and 45.00 kg/m2 were their minimum and 
maximum BMI, respectively. 
4.1.1 All cancers combined 
During the 446,821 person-years of the follow-up period (average follow-up: 22.41 years), a 
total of 2,248 cancer incidents were identified. 1,252 (55.7%) of the cancers were found in 
men while 996 (44.3%) were in women. However, it should be noted that the age range of 
men in the study was 20-61 years while that of women was 20-56 years. 
The mean BMI of men who had cancer during the follow-up period was 25.11 kg/m2and that 
of those who did not have cancer throughout was 24.54 kg/m2. For women, the mean BMI 
of those who had cancer during the follow-up period was 23.61 kg/m2while that of those 
who did not have cancer was 23.03 kg/m2. Thus, the difference in the means BMI between 
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those who had cancer and those who did not have cancer was 0.57 kg/m2 for men and 0.58 
kg/m2 for women (p-values of the differences < 0.001 in both genders) (Table 1). 
Table 1 - The Tromsø Study (Tromsø 3): Characteristics of the Study Population - numbers, 
percentages, means and standard deviations (SD) 
CHARACTERISTICS MEN WOMEN 
Study population 10,219 9,724 
Person-years of follow-up 224,648 222,173 
Mean follow-up period in years 21.98 22.85 
Number of cancers identified 1,252 996 
Percentage of population with cancer 12.3 10.2 
Follow-up time [in person-years] 224,648 222,173 
Crude incidence rate [per 100,000 person-years] 557 448 
Mean age in years (SD) 38.61 (11.06) 36.31 (9.63) 
Mean BMI in kg/m
2
 (SD) 24.61 (3.04) 23.09 (3.48) 
Mean BMI in kg/m
2
of people with no cancers (SD) 24.54 (3.01) 23.03 (3.47) 
Mean BMI in kg/m
2
of people with cancers (SD) 25.11 (3.16) 23.61 (3.56) 
Difference in kg/m
2
 between mean BMI for cancer and no cancer 
population (p-value) 
0.57 (<0.001) 0.58 (<0.001) 
 
4.1.2 Cancer by primary sites 
Prostate cancer was the most common cancer in the follow-up period. This was followed by 
breast cancer; lung and tracheal cancer; and colon cancer, in that order. Table 2 shows the 
12 most common cancers in the study population during the follow-up period. 
Table 2 - The Tromsø Study (Tromsø 3): Incident Cancers by Primary Site (using International 
Classification of Diseases, 10th edition (ICD 10)) in Men and Women 
CANCERS ICD 10 CODES NUMBER (%) MEN WOMEN 
Prostate C61 346 (15.4) 346 NA 
Breast C50 315 (14.0) 2 313 
Lung, Trachea C33-34 264 (11.7) 176 88 
Colon C18 181 (8.1) 102 79 
Bladder, Ureter, Urethra C66-68 108 (4.8) 86 22 
Rectum, Recto-sigmoid, Anus C19-21 101 (4.5) 69 32 
Melanoma (Skin) C43 87 (3.9) 47 40 
Non-Hodgkin Lymphoma C82-85, C96 82 (3.6) 48 34 
Stomach C16 74 (3.3) 50 24 
Pancreas C25 62 (2.8) 40 22 
Ovary C56 58 (2.6) NA 58 
Leukaemia C91-95, D45-47 56 (2.5) 34 22 
Other cancers  514 (22.9) 252 262 




4.2 Body Mass Index (BMI) and Total Cancer Incidence 
In the unadjusted analyses, the percentages of the population with cancer incident in the 
four BMI categories generally increase with increasing BMI. For the men, it was 10.8%, 
10.6%, 14.3% and 16.5% for low weight, normal weight, overweight and obese people, 
respectively, and for the women, it was 7.1%, 10.2%, 12.3% and 12.7% for women with low 
weight, normal weight, overweight and obese, respectively. The crude incidence rate of 
cancer in men was 557 per 100,000 men-years while that of women was 448 per 100,000 
women-years (Table 1 and 3). 
Table 3 - The Tromsø Study (Tromsø 3): Distribution of all cancers (combined) according to the four 
BMI categories in Men and Women 
MEN 
BMI categories (in kg/m
2
) Population Cancer (%) Person-years *Crude IR  
Low weight (BMI < 20.0) 389 42 (10.8) 8,588 489 
Normal Weight (BMI 20.0-24.9) 5,685 605 (10.6) 127,100 476 
Overweight (BMI 25.0-29.9) 3,636 521 (14.3) 78,397 665 
Obese (BMI ≥ 30.0) 509 84 (16.5) 10,562 795 
TOTAL 10,219 1,252 (12.3) 224,648 557 
     
WOMEN 
Low weight (BMI < 20.0) 1,410 100 (7.1) 32,749 305 
Normal Weight (BMI 20.0-24.9) 6,117 624 (10.2) 140,187 445 
Overweight (BMI 25.0-29.9) 1,740 214 (12.3) 39,011 549 
Obese (BMI ≥ 30.0) 457 58 (12.7) 10,226 567 
TOTAL 9,724 996 (10.2) 222,173 448 
*Crude IR = Crude incidence rate per 100,000 person-years 
 
4.3 Relationships between BMI and total cancer incidence 
The relative risk of the total cancer incidence (all cancers combined) according to the BMI 
grouping was estimated using the Cox proportional hazard regression model, with normal 
weight (BMI of 20.0-24.9 kg/m2) as the reference, and adjusted for age and smoking status. 
After adjusting for age and smoking, both the low weight and obese were associated with 
increased risk of cancer in men, whereas no relationship was found in women (Table 4). 
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Table 4 - The Tromsø Study (Tromsø 3): Relationship between BMI and total cancer incidence with 
Hazard Ratios (HR 95% confidence limits) in Men and Women 
MEN 
BMI categories (in kg/m
2
) Age adjusted HR (95% CI) Age and smoking adjusted 
HR (95% CI) 
Low weight (BMI < 20.0) 1.54 (1.12-2.10) 1.41 (1.03-1.93) 
Normal Weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 1.00 (0.89-1.13) 1.04 (0.93-1.18) 
Obese (BMI ≥ 30.0) 1.21 (0.96-1.52) 1.30 (1.03-1.63) 
P-value for homogeneity 0.020 0.032 
P-value for linear trend 0.97 0.34 
WOMEN 
Low weight (BMI < 20.0) 0.87 (0.71-1.08) 0.85 (0.69-1.05) 
Normal Weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 0.96 (0.82-1.12) 0.97 (0.83-1.14) 
Obese (BMI ≥ 30.0) 0.97 (0.74-1.27) 1.00 (0.76-1.31) 
P-value for homogeneity 0.64 0.52 
P-value for linear trend 0.76 0.49 
HR = hazard ratio; 95% CI = 95% confidence interval; *ref. cat. = reference category 
 
Furthermore, the data from the two genders were merged and additional adjustment for 
sex and interaction term - sex and BMI were included in the model. This was to assess 
whether the effects of BMI on total cancer incidence were statistically different by sex. The 
p-value for interaction by sex was 0.043, which shows the effects were significantly different 
by sex. Figure 1 illustrates the relationships found in men and women. 
Figure 4 - The Tromsø Study (Tromsø 3): Relative risks of all cancers combined in men and women 























The above relationship did not change in both genders even when the first 5 years of the 
study was excluded from the analyses. 
4.4 Analyses of Cancers by Primary sites 
4.4.1 Prostate Cancer 
Prostate cancer was the most common cancer in the study with 346 incident cases. It 
accounted for 27.6% of all the cancers in men. The crude incidence rate of prostate cancer 
in the study population was 153 per 100,000 men-years (Table 5).   
Table 5 - The Tromsø Study (Tromsø 3): Distribution of Prostate cancer according to the four BMI 
categories 
MEN  
BMI categories (in kg/m
2
) Population of men Prostate cancer (%) Person-years *Crude IR  
Low weight (BMI < 20.0) 389 7 (1.8) 8,612 81 
Normal Weight (BMI 20.0-24.9) 5,685 175 (3.1) 127,610 137 
Overweight (BMI 25.0-29.9) 3,636 146 (4.0) 78,874 185 
Obese (BMI ≥ 30.0) 509 18 (3.5) 10,646 169 
TOTAL 10,219 346 (3.4) 225,742 153 
*Crude IR = Crude incidence rate per 100,000 person-years 
The mean BMI of men with incident prostate cancer was 25.03 kg/m2, whereas those with 
no prostate cancer had mean BMI of 24.60 kg/m2. The difference in the means BMI was 0.43 
kg/m2 (p-value = 0.009). However, when adjusted for age and smoking status, and normal 
weight (BMI between 20.0 and 24.9 kg/m2) used as the reference category, essentially, no 
relationship was found between BMI and the risk of prostate cancer (Table 6 and Figure 5). 
Table 6 - The Tromsø Study (Tromsø 3): Relationships between BMI and prostate cancer incidence 
with Hazard ratios (95% confidence limits) 
MEN  
BMI categories (in kg/m
2
) Age adjusted HR (95% CI) Age & smoking adjusted HR 
(95% CI) 
Low weight (BMI < 20.0) 0.94 (0.44-2.00) 0.93 (0.44-2.00) 
Normal Weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 0.96 (0.77-1.20) 0.97 (0.77-1.21) 
Obese (BMI ≥ 30.0) 0.90 (0.55-1.46) 0.90 (0.56-1.47) 
P-value for homogeneity 0.96 0.97 
P-value for linear trend 0.66 0.70 
HR = hazard ratio; 95% CI = 95% confidence interval; *ref. cat. = reference category 
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When men diagnosed within 3 years from baseline (start of follow-up) were excluded from 
the analyses, we observed no material change in the estimates of the relative risk associated 
with the BMI categories. 




4.4.2 Lung and Tracheal Cancers 
Lung and tracheal cancers were the third most common cancer after prostate and breast 
cancers in the study population. As there were no cases of tracheal cancer, the results 
essentially reflect relationships with lung cancers and we hereafter referred to them as 
such. Lung cancer was the second most common in men (after prostate cancer) and the 
second most common in women (after breast cancer). It accounted for 264 cancer cases 
which was 11.7% of all the cancer incidents within the follow-up period. There were 176 
cases in men with the crude incidence rate of 78 per 100,000 men-years, and 88 cases in 






















Table 7 - The Tromsø Study (Tromsø 3): Distribution of Lung cancers according to the BMI 
categories in Men and Women 
MEN 
BMI categories (in kg/m
2
) Population Cancer (%) Person-years *Crude IR  
Low weight (BMI < 20.0) 389 9 (2.3) 8,626 104 
Normal Weight (BMI 20.0-24.9) 5,685 83 (1.5) 127,702 165 
Overweight (BMI 25.0-29.9) 3,636 69 (1.9) 78,960 87 
Obese (BMI ≥ 30.0) 509 15 (2.9) 10,663 141 
TOTAL 10,219 176 (1.7) 225,951 78 
     
WOMEN 
Low weight (BMI < 20.0) 1,410 13 (0.9) 32,830 40 
Normal Weight (BMI 20.0-24.9) 6,117 55 (0.9) 140,682 40 
Overweight (BMI 25.0-29.9) 1,740 14 (0.8) 39,268 36 
Obese (BMI ≥ 30.0) 457 6 (1.3) 10,314 58 
TOTAL 9,724 88 (0.9) 223,094 40 
*Crude IR = Crude incidence rate per 100,000 person-years 
 
The mean BMI of men who had lung cancer was 24.93 kg/m2, whereas that of men who did 
not was 24.61 kg/m2. The mean BMI of women who had lung cancer was 23.14 kg/m2 while 
that of women who did not have the cancer was 23.09 kg/m2. The difference in the means 
BMI between those who had cancer and those who did not was 0.32 kg/m2 for men and 
0.05 kg/m2 for women, and the corresponding p-values for these differences were 0.16 and 
0.90 respectively. 
As expected, the highest percentage of the lung cancers were found in the current smokers 
(compared to ex- and never-smokers). However, the current smokers in the low weight 
category bear the highest proportion of the lung cancer in both men and women (Table 8). 
Almost all the people who had lung cancers in the low weight category are current smokers 







Table 8 - The Tromsø Study (Tromsø 3): Distribution of Lung Cancer according to BMI Categories 
and Smoking Status in Men and Women 
SEX BMI CATEGORIES SMOKING STATUS NO LUNG CANCER LUNG CANCER (%) TOTAL 
MEN Low weight Current-smoker  252 8  (88.9) 260 
  Ex-smoker 47 0  (0.0) 47 
  Never-smoker 81 1  (11.1) 82 
  Sub-total 380 9  (100.0) 389 
 Normal weight Current-smoker  2697 69  (83.1) 2766 
  Ex-smoker 1147 11  (13.3) 1158 
  Never-smoker 1758 3  (3.6) 1761 
  Sub-total 5602 83  (100.0) 5685 
 Overweight Current-smoker  1419 54  (78.3) 1473 
  Ex-smoker 1137 14  (20.3) 1151 
  Never-smoker 1011 1  (1.4) 1012 
  Sub-total 3567 69  (100.0) 3636 
 Obese Current-smoker  177 10  (66.7) 187 
  Ex-smoker 170 5  (33.3) 175 
  Never-smoker 147 0  (0.0) 147 
  Sub-total 494 15  (100.0) 509 
WOMEN Low weight Current-smoker  805 12  (92.3) 817 
  Ex-smoker 199 1  (7.7) 200 
  Never-smoker 393 0  (0.0) 393 
  Sub-total 1397 13  (100.0) 1410 
 Normal weight Current-smoker  2802 40  (72.7) 2842 
  Ex-smoker 1196 6  (10.9) 1202 
  Never-smoker 2064 9  (16.4) 2073 
  Sub-total 6062 55  (100.0) 6117 
 Overweight Current-smoker  706 11  (78.6) 717 
  Ex-smoker 341 1  (7.1) 342 
  Never-smoker 679 2  (14.3) 681 
  Sub-total 1726 14  (100.0) 1740 
 Obese Current-smoker  167 4  (66.7) 171 
  Ex-smoker 92 0  (0.0) 92 
  Never-smoker 192 2  (33.3) 194 
  Sub-total 451 6  (100.0) 457 
Table 9 - The Tromsø Study (Tromsø 3): Relationship between BMI and Lung Cancer incidence with 
the Hazard Ratios (HR 95% confidence limits) in Men and Women 
MEN  
BMI categories (in kg/m
2
) Age adjusted HR (95% CI) Age & smoking adjusted HR (95% CI) 
Low weight (BMI < 20.0) 2.50 (1.26-4.99) 1.82 (0.91-3.62) 
Normal Weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 0.92 (0.67-1.27) 1.09 (0.79-1.50) 
Obese (BMI ≥ 30.0) 1.46 (0.84-2.53) 2.03 (1.17-3.53) 
P-value for homogeneity 0.021 0.037 
P-value for linear trend 0.63 0.30 
WOMEN   
Low weight (BMI < 20.0) 1.54 (0.83-2.83) 1.32 (0.72-2.43) 
Normal Weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 0.60 (0.33-1.07) 0.67 (0.37-1.21) 
Obese (BMI ≥ 30.0) 0.94 (0.40-2.18) 1.13 (0.48-2.63) 
P-value for homogeneity 0.12 0.36 
P-value for linear trend 0.063 0.25 
HR = hazard ratio; 95% CI = 95% confidence interval; *ref. cat. = reference category 
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Table 9 (above) gives the results for lung cancer stratified by gender. 
To assess whether the effect of BMI on lung cancer incidence were statistically different by 
sex, the data from the two genders were merged and additional adjustment for sex and 
interaction term - sex and BMI were included in the model. The p-value for interaction by 
sex was 0.45, which shows the effects were not significantly different by sex. Therefore, the 
data from men and women were merged to increase power. In the age and smoking status 
adjusted analyses of the merged data, normal weight was used as the reference category, 
and the hazard ratios and 95% confidence intervals were: low weight 1.55 (0.98-2.45); 
overweight 0.96 (0.73-1.26); and obese 1.67 (1.05-2.65). The p-values for homogeneity and 
linear trend were 0.036 and 0.89 respectively. This is a U-shaped relationship similar to the 
one observed in men (alone) (Figure 6). The U-shaped relationship was statistically 
confirmed (p-value of second order term = 0.004). 
Figure 6 - The Tromsø Study (Tromsø 3): Relative Risks of Lungs in Men and Women according to 


























In a separate analysis, we merged the data of the never- and ex-smokers (of more than 5 
years), and used the low and normal weight categories as the reference (because of the 
small numbers). The hazard ratios and 95% confidence intervals in men were: overweight 
0.86 (0.37-2.00); obese 1.56 (0.43-5.66); and in women: overweight 0.48 (0.10-2.20); obese 
1.58 (0.34-7.34). The p-value for linear trend was 0.79 in men and 0.98 in women, while the 
p-value for homogeneity was 0.65 in men and 0.48 in women (Figure 7). 
Figure 7 - The Tromsø Study (Tromsø 3): Relative Risks of Lungs Cancers in Never- and Ex-smokers 
(of more than 5 years) in Men and Women according to the BMI categories 
 
 
4.4.3 Colon Cancer 
Colon cancer was the third commonest cancer in both men and women in the study 
population. It accounted for 8% of all the cancers in the follow-up period with a total of 181 
incident cases. There were 102 cases in the men with the crude incidence rate of 45 per 






















As there were no incident colon cancer in men with low weight and few in women with low 
weight, subjects in low and normal weight categories were merged for all the analyses done 
for colon cancer incidents. Nevertheless, we noted that there were 389 men with low 
weight among the 6,074 low/normal weight category. For the women, there were 1,410 
with low weight among the 7,527 low/normal weight category, and there were 6 colon 
cancer incidents among the 1,410 low weight women. 
Table 10 - The Tromsø Study (Tromsø 3): Distribution of Colon cancers according to the BMI 
categories 
MEN 
BMI categories (in kg/m
2
) Population Cancer (%) Person-years *Crude IR  
Low/normal weight (BMI <25.0) 6,074 37 (0.6) 136,383 27 
Overweight (BMI 25.0-29.9) 3,636 57 (1.6) 78,972 72 
Obese (BMI ≥ 30.0) 509 8 (1.6) 10,660 75 
TOTAL 10,219 102 (1.0) 226,015 45 
WOMEN 
Low/ Normal weight (BMI <25.0) 7,527 56 (0.7) 173,526 32 
Overweight (BMI 25.0-29.9) 1,740 18 (1.0) 39,257 46 
Obese (BMI ≥ 30.0) 457 5 (1.1) 10,314 49 
TOTAL 9,724 79 (0.8) 223,097 35 
*Crude IR = Crude incidence rate per 100,000 person-years 
 
The mean BMI of men who had colon cancer was 26.10 kg/m2, whereas that of men who did 
not have colon cancer was 24.60 kg/m2. For women, the mean BMI of those who had colon 
cancer was 23.83 kg/m2 while that of those who did not have was 23.09 kg/m2. The 
difference in the means BMI between those who had cancer and those who did not was 
1.50 kg/m2 for men and 0.74 kg/m2 for women, and the corresponding p-values for the 
differences were <0.001 and 0.057 respectively. 
When adjusted for age and smoking status, and low and normal weight (BMI less than 25.0 
kg/m2) used as the reference category, a linear relationship was found between BMI and the 
risk of colon cancer in men, while it was null in women (Table 11 and Figure 8). The p-value 
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for linear trend was 0.010 in men and 0.84 in women, indicating an association in men but 
not in women (Table 11 and Figure 8). 
The relationship did not attenuate after the first 3 years of the follow-up period was 
excluded from the analyses. 
Table 11 - The Tromsø Study (Tromsø 3): Relationship between BMI and Colon cancer incidence 
with the Hazard Ratios (HR 95% confidence limits) 
MEN  
BMI categories (in kg/m
2
) Age adjusted HR (95% CI) Age & smoking adjusted HR (95% CI) 
Low/normal weight (BMI<25.0) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 1.81 (1.19-2.74) 1.77 (1.16-2.70) 
Obese (BMI ≥ 30.0) 1.89 (0.88-4.07) 1.83 (0.85-3.95) 
P-homogeneity 0.016 0.023 
P-value for linear trend 0.006 0.010 
   
WOMEN   
Low/normal weight (BMI<25.0) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 0.94 (0.55-1.61) 0.94 (0.54-1.61) 
Obese (BMI ≥ 30.0) 0.95 (0.38-2.40) 0.97 (0.38-2.43) 
P-value for homogeneity 0.97 0.97 
P-value for linear trend 0.83 0.84 
HR = hazard ratio; 95% CI = 95% confidence interval; *ref. cat. = reference category 
 
Figure 8 - The Tromsø Study (Tromsø 3): Relative risks of Colon Cancer in Men and Women 


























When the BMI was entered as a continuous variable (that is, in single unit BMI increment), 
and age and smoking status corrected, the relative risk for men was 1.10 (95% CI 1.04-1.17) 
with the p-value of 0.002. For women, no relationship was indicated (p-value = 0.96).  
The data of the women was then stratified into 2 by age 36 years at baseline (36.31 years 
was the mean age of the women cohort at the study baseline), thus having 2 groups of 
women: those below 36 years and those above 36 years. The results from the stratified 
analyses are given in Table 12 and Figure 9. 
 
Table 12 - The Tromsø Study (Tromsø 3): Relationship between BMI and Colon cancer incidence 
with the Hazard Ratios (HR 95% confidence limits) stratified by mean age (36 years) 
 Women < 36 years at baseline Women ≥ 36 years at baseline 
BMI Categories (in kg/m
2
) *HR (95% CI) *HR (95% CI) 
Low/normal weight (BMI<25.0) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 2.09 (0.57-7.58) 0.82 (0.46-1.48) 
Obese (BMI ≥ 30.0) 5.26(1.15-24.06) 0.60 (0.19-1.95) 
P-value for homogeneity 0.078 0.61 
P-value for linear trend 0.026 0.32 
WHEN THE FIRST 3 YEARS OF BASELINE WAS EXCLUDED  
Low/normal weight (BMI<25.0) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 2.09 (0.57-7.58) 0.83 (0.45-1.52) 
Obese (BMI ≥ 30.0) 5.26 (1.15-24.06) 0.65 (0.20-2.11) 
P-value for homogeneity 0.078 0.68 
P-value for linear trend 0.026 0.38 
*HR = Age and smoking adjusted hazard ratio; 95% CI = 95% confidence interval; *ref. cat. = reference category 
 
A positive linear relationship was found in the relatively young women.  
When the BMI was entered as a continuous variable (in single unit increment), the relative 
risk for women below 36 years (at baseline) was 1.13 (95% CI 1.00-1.26) with the p-value of 
0.044. For women of 36 years and above, it was 0.97 (95% CI 0.90-1.04) with p-value of 0.4, 




Figure 9 - The Tromsø Study (Tromsø 3): Relative risks of Colon Cancer in Women < 36 year and 
Women ≥ 36 years (at baseline) according to BMI categories 
 
In another analysis, we considered the age at colon cancer diagnosis and used data of 
women who had cancer at 55 years and below for the model. The results showed a similarly 
positive association between increased BMI and risk of colon cancer in this group. 
(Low/normal weight as the reference category, overweight: HR=1.13, 95% CI=0.37-3.44, 
obese: HR=2.15, 95% CI=0.49-9.50). However, the relationship was not statistically 
significant. 
4.4.4 Cancers of the Rectum, Recto-sigmoid and Anus 
There were 101 incident cancers of the rectum, recto-sigmoid and the anus. As there were 
only 3 cases of anal cancer, the results basically reflect relationships with cancers of the 
rectum and recto-sigmoid, and we therefore refer to them as such hereafter. Rectal and 
recto-sigmoidal cancers accounted for 4.5% of all the cancers in the follow-up period. There 
were 69 cases in the men with the crude incidence rate of 31 per 100,000 men-years, and 
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Table 13 - The Tromsø Study (Tromsø 3): Distribution of Cancers of Rectum and Recto-sigmoid 
according to the BMI categories 
MEN 
BMI categories (in kg/m
2
) Population Cancer (%) Person-years *Crude IR  
Low weight (BMI < 20.0) 389 2 (0.5) 8,627 23 
Normal Weight (BMI 20.0-24.9) 5,685 30 (0.5) 127,755 24 
Overweight (BMI 25.0-29.9) 3,636 31 (0.9) 78,994 39 
Obese (BMI ≥ 30.0) 509 6 (1.2) 10,672 56 
TOTAL 10,219 69 (0.7) 226,046 31 
     
WOMEN 
Low weight (BMI < 20.0) 1,410 5 (0.4) 32,842 15 
Normal Weight (BMI 20.0-24.9) 6,117 18 (0.3) 140,717 13 
Overweight (BMI 25.0-29.9) 1,740 6 (0.3) 39,271 15 
Obese (BMI ≥ 30.0) 457 3 (0.7) 10,317 29 
TOTAL 9,724 32 (0.3) 223,147 14 
*Crude IR = Crude incidence rate per 100,000 person-years 
 
The mean BMI of men who had cancer of the rectum and recto-sigmoid was 25.54 kg/m2, 
whereas that of men who did not was 24.60 kg/m2. For women, the mean BMI of those who 
had the cancer was 23.53 kg/m2 while that of those who did not was 23.09 kg/m2. The 
difference in the means BMI between those who had the cancer and those who did not was 
0.94 kg/m2 for men and 0.44 kg/m2 for women, and the corresponding p-values for the 
differences were 0.01 and 0.48 respectively. 
 
Table 14 - The Tromsø Study (Tromsø 3): Relationship between BMI and incidence of the Cancer of 
the Rectum and Recto-sigmoid with the Hazard Ratios (HR 95% confidence limits) 
MEN  
BMI categories (in kg/m
2
) Age adjusted HR (95% CI) Age & smoking adjusted HR (95% CI) 
Low weight (BMI < 20.0) 1.41 (0.34-5.92) 1.32 (0.31-5.57) 
Normal weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 1.25 (0.75-2.07) 1.30 (0.78-2.16) 
Obese (BMI ≥ 30.0) 1.80 (0.75-4.35) 1.92 (0.79-4.65) 
P-value for homogeneity 0.57 0.48 
P-value for linear trend 0.25 0.18 
WOMEN   
Low weight (BMI < 20.0) 1.43 1.43 (0.52-3.91) 
Normal weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 0.99 1.00 (0.39-2.55) 
Obese (BMI ≥ 30.0) 1.84 1.89 (0.55-6.51) 
P-value for homogeneity 0.72 0.70 
P-value for linear trend 0.87 0.84 
HR = hazard ratio; 95% CI = 95% confidence interval; *ref. cat.  = reference category 
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Figure 10 - The Tromsø Study (Tromsø 3): Relative risks of Cancer of Rectum and Recto-sigmoid in 
Men and Women according to BMI categories 
 
 
The relationships between BMI and the risk of rectal and recto-sigmoid cancers appeared U-
shaped (Figure 10), however, the p-value for the second order term was 0.51 in men and 
0.25 in women. 
Unlike in colon cancer, stratification by the mean age of the women cohort (36 years) has no 
new profound effect modification on the risk of the cancers in the women. 
4.4.5 Colorectal Cancers 
There were 101 incident cancers in the rectum, recto-sigmoid colon and the anus. This 
constituted 4.5% of all the cancer incidents in the study population. When these were 
added to the colon cancers, there were 282 cases which represented 12.6 per cent of all the 
cancers identified in the follow-up period. 171 cases of these cancers were found in men, 
with the crude incidence rate of 76 per 100,000 men-years, while 111 cases occurred in 





















Table 15 - The Tromsø Study (Tromsø 3): Distribution of Colorectal Cancer according to the BMI 
categories 
MEN 
BMI categories (in kg/m
2
) Population Cancer (%) Person-years *Crude IR  
Low weight (BMI < 20.0) 389 2 (0.5) 8,627 23 
Normal Weight (BMI 20.0-24.9) 5685 67 (1.2) 127,726 53 
Overweight (BMI 25.0-29.9) 3636 88 (2.4) 78,922 112 
Obese (BMI ≥ 30.0) 509 14 (2.8) 10,659 131 
TOTAL 10,219 171 (1.7) 225,934 76 
     
WOMEN 
Low weight (BMI < 20.0) 1,410 11 (0.8) 32,838 34 
Normal Weight (BMI 20.0-24.9) 6,117 68 (1.1) 140,664 48 
Overweight (BMI 25.0-29.9) 1,740 24 (1.4) 39,250 61 
Obese (BMI ≥ 30.0) 457 8 (1.8) 10,314 78 
TOTAL 9,724 111 (1.1) 223,065 50 
*Crude IR = Crude incidence rate per 100,000 person-years 
The mean BMI of men with colorectal cancer was 25.87 kg/m2 whereas men with no such 
cancer had mean BMI of 24.59 kg/m2. Women with colorectal cancer had mean BMI of 
23.74 kg/m2 while women with no such cancer had 23.08 kg/m2 as their mean BMI value. 
The difference in the means BMI between those who had colorectal cancer and those who 
did not was 1.28 kg/m2 for men and 0.65 kg/m2 for women, and the corresponding p-values 
were <0.001 and 0.047 respectively. 
Table 16 - The Tromsø Study (Tromsø 3): Relationship between BMI and Colorectal Cancer 
incidence with the Hazard Ratios (HR 95% confidence limits) 
MEN  
BMI categories (in kg/m
2
) Age adjusted HR (95% CI) Age & smoking adjusted HR (95% CI) 
Low weight (BMI < 20.0) 0.67 (0.16-2.74) 0.66 (0.16-2.72) 
Normal weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 1.52 (1.10-2.10) 1.53 (1.11-2.11) 
Obese (BMI ≥ 30.0) 1.81 (1.01-3.22) 1.82 (1.02-3.26) 
P-value for homogeneity 0.030 0.028 
P-value for linear trend 0.003 0.003 
WOMEN   
Low weight (BMI < 20.0) 0.94 (0.49-1.78) 0.95 (0.50-1.80) 
Normal weight (BMI 20.0-24.9) *ref. cat. 1.00 1.00 
Overweight (BMI 25.0-29.9) 0.93 (0.58-1.49) 0.93 (0.58-1.50) 
Obese (BMI ≥ 30.0) 1.14 (0.55-2.39) 1.16 (0.57-2.44) 
P-value for homogeneity 0.96 0.96 
P-value for linear trend 0.86 0.84 




In the age and smoking status adjusted analyses, the p-value for linear trend was 0.003 for 
men and 0.84 for women, indicating a relationship in men, but not in women. 
Figure 11 - The Tromsø Study (Tromsø 3): Relative Risks of Colorectal Cancers in Men and Women 
according to BMI categories 
 
 
When the BMI was entered into the Cox regression model as a continuous variable (in single 
unit increment), the resulting relative risk for men was 1.09 (95% CI 1.04-1.14) with a p-
value of 0.001. For women, the p-value was 0.98, thus, no relationship was found in women. 
In a separate analyses and as done in the colon cancer, we limit the analyses in women to 
those aged 36 years and below (at baseline), we found a linear relationship between BMI 
and the risk of colorectal cancer, though not statistically significant (HR=1.31, 95% CI = 0.73-
2.36, p-value of linear trend = 0.37). When women aged 36 years and above (at baseline) 
were analysed, no relationship was found (HR=0.97, 95% CI=0.72-1.31, p-value of linear 



























CHAPTER 5: DISCUSSION 
5.1 All cancers combined 
In this population based prospective study, we found a U-shaped relationship between BMI 
and total cancer incidence in men during a mean of 21.98 years of follow-up. The U-shaped 
relationship did not change even when the first 5 years of the follow-up period was 
excluded from the analyses. This means that it is unlikely that the increased risk in the low 
weight and obese men is due to preclinical disease. Unlike in men, there was essentially no 
relationship between BMI and the total incident cancers in women (Table 4 and Figure 4). 
The findings are similar to the results of a study conducted by Inove, Sobne and Tsugane 
(2004) in Japan where they also observed a U-shaped increased risk of cancer occurrence 
according to the BMI categories in men and little or no fluctuation in the risk in women of 
different BMI categories (45). On the contrary, Calle et al (2003) found increased BMI 
associated with increased risk of incident cancers in both men and women. However, they 
did not explore the relationship in the underweight subjects (16). 
There are possibilities of several mechanisms for the effects of a low or high BMI on the risk 
of cancer, and attempts have been made to explain the U-shaped risk variation according to 
BMI categories seen in men. It was suggested that the increased risk of all cancers combined 
in the low weight BMI category may be caused by “oxidative DNA stress” or mild 
inflammations common in the underweights. The immune system may be damaged by 
these inflammations, thus allowing cancer cells to proliferate (42, 46). Malnutrition may also 
reduce immune responses and weaken resistance to infection which may also increase risk 
of cancer occurrence (45, 47). The increased risk in the overweight and obesity may 
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however, be explained by different mechanisms of insulin-like growth factor-1 (IGF-1), sex 
steroids and abdominal obesity. These mechanisms, described earlier in this thesis (see 
literature review section) may explain the increase in cancer risk with increasing adiposity. 
Animal studies have also revealed that over-nutrition may also reduce immunity which may 
lead to increased risk of cancer (45, 48). However, obesity has no substantial effects on the 
total cancer occurrence in women. The mechanism(s) responsible for the observed different 
cancer risk patterns according to genders (for all cancers combined) remained largely 
unclear (45). 
The public health implication of these findings is that very low or high BMI in otherwise 
healthy population may have critical association for future development of cancers (45), and 
health policies may hence be to encourage reduction of body weight as low as possible but 
above the low weight category, particularly in men. 
5.2 Prostate Cancer 
We found no marked variation in the risk of prostate cancer in relation to BMI. However, 
there was a slight reduction in the risk in the obese, although not statistically significant 
(Table 6 and Figure 5). 
The epidemiologic evidence linking BMI and prostate cancer is rather controversial. Some 
studies have revealed increased BMI to be associated with decreased risk of prostate cancer 
(49, 50), others found increased risk (51, 50), while some studies found no clear association 
of risk (50, 52, 53). In a 21-year follow-up of 950,000 Norwegian men, obese men were 
found to have 9% increased risk of prostate cancer, while the obese men aged 50 to 59 
years at the end of the follow-up had a 58% increased risk (54). Therefore, some 
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interactions between age and obesity may account for why some studies found increased 
risk and others no relationship between increasing BMI and prostate cancer risk (50). 
Our study investigated men aged 61 years and younger (at baseline). In a similar study by 
Giovannucci et al (2003) where men younger than 60 years were studied, they found 
increased BMI to be associated with decreased risk of prostate cancer (55). However, 
Renehan (2011) considered that this may only be apparent as he opined that “there is an 
inherent bias in a clinician’s ability to detect prostate cancer in obese men as larger sized 
prostates make biopsy less accurate for finding an existing cancer” (30). 
The mechanism for decrease risk of prostate cancer in obese individuals is unclear but 
thought to be associated with hormones (55). The raised circulating level of leptin in obese 
men may decrease the androgen (such as testosterone) in them (55, 56), and the lowered 
testosterone level associated with obesity may account for the decreased risk of prostate 
cancer (55). 
The public health implication of this is, even if obesity slightly decreases the risk of prostate 
cancer, the overall effects of obesity are overwhelmingly detrimental to the general health 
status (55). 
5.3 Lung Cancer 
We found a U-shaped relationship between BMI and the risk of lung cancer. Thus, the 
underweight and the obese are at higher risk of lung cancer compared to the normal weight 
category. From the unadjusted descriptive statistics (Table 8), almost all the people who had 
lung cancers in the low weight category are current smokers. Therefore, low weight subjects 
who smoke may be at higher risk of lung cancer. It is an established observation that 
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smokers have lower mean BMI (30). But then, whatever is the cause of the low BMI, either 
due to the current smoking status, or it predates smoking, a low BMI correlates with an 
increased risk of lung cancer. As we have adjusted for smoking, the impact of smoking on 
BMI-lung cancer relationship should be minimized. However, it is rather difficult to fully 
adjust for this strong risk factor for the disease, and we would expect residual confounding 
by smoking.   
This finding re-echoes the result of the prospective study of Koh et al (2009) conducted in 
Singapore Chinese Health Study which concluded that smokers with low BMI may be at 
higher risk of lung cancer (18). 
The other (right) half side of the U-shaped relationship in our findings (Figure 6) shows 
increased BMI with increased risk of lung cancer in men, whereas the relationship 
approximately fluctuates around the null in women. Most of the risk observed seems to be 
for men in the highest BMI category (Table 9). 
In the exclusive analysis of never- and former smokers of more than 5 years (in an attempt 
to minimize the smoking factor and explore the BMI-lung cancer relationship more), both 
obese men and women show increased risk of lung cancer (Figure 7). However, this is not 
statistically significant in both genders. Even then, 5 years post smoking cessation also may 
not be long enough time to completely exclude the smoking factor. 
Our findings here is analogous to Rauscher, Mayne and Janerich (2000) in a case-control 
study where they found 2.6 fold increased odds ratio for lung cancer in never- and former-




The results of studies in this area, especially the relationship between BMI and never-
smokers, have been conflicting (57). While some studies have reported positive association 
(58), many have given evidence of inverse association (59), and others have shown no 
association at all (60). Nevertheless, the results of the current analyses are consistent with 
BMI-cancer association found in some other cancer sites, and similar biological mechanism 
or theories have been used to provisionally explain the association. 
In the case of low BMI and its association with increased risk of lung cancer, studies have 
shown that decrease in BMI inversely relate with the level of marker in the urine called 8-
hydroxydeoxyguanosine, which is a marker of oxidative DNA damage in smokers (61.) Thus, 
BMI may act as an independent indicator for vulnerability to smoking-related cancer (62). 
Furtherance to this, smoking may also cause decrease in BMI via weight loss by enhancing 
metabolic rate, which also bring about a carcinogenic pathway through higher production of 
cellular reactive biological substances (62). 
The public health implications of our findings are the possible increased lung cancer risk in 
smokers in the low weight population who may usually be predominantly young adults, and 
also the increased risk in the obese. These important implications further highlight the 
imperativeness of keeping healthy body weight 
5.4 Colon Cancer 
Our results confirm that increased BMI is a strong risk factor for colon cancer in men. No 
association was found in women (Table 11 and Figure 8).  
Our findings in men are consistent with several studies where increased BMI have been 
reported for increased risk of colon cancer in men (63-67). Meanwhile, other studies have 
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either found weak or null association between BMI and risk of colon cancer in women (63, 
67). However, when the analyses were restricted to the women aged 36 years and below at 
baseline (36 years is the mean age of the female cohort), we observed a relatively strong 
positive association between BMI and the risk of colon cancer (Figure 9). This association 
was not altered even when the first 3 years of the follow-up period was excluded from the 
analyses (Table 12), which means the relationship is not as a result of preclinical disease. 
Conversely, when data of women aged 36 years and above (at baseline) were alternatively 
used for the analyses, the association was, as expected, negative, but not statistically 
significant (Table 12). 
These findings suggest that BMI may be an important predictor of colon cancer occurrence 
in relatively young women, but its effects weaken by age, or probably by menopausal status 
as Giovannucci (2001) suggested, (68). Thus, menopausal status is a possible effect modifier 
of BMI and colon cancer risk relationship. 
Our findings in women are similar to the results of the study conducted by Terry, Miller and 
Rohan (2002) in Canada where a cohort aged 40-76 years at baseline were investigated. 
When they confined their analyses to women below 55 years at baseline (the mean age of 
their women cohort was 55 years), they found strong association between BMI and colon 
cancer risk, but no association was found among women aged 55 years and above at 
baseline (69). Nevertheless, there are divergent findings in some studies where increased 
body size in older women was reportedly associated with colon cancer risk (70). 
The exact biological mechanism responsible for our observation is not fully understood (71), 
but it is believed to be closely related to insulin, insulin-like growth factor (IGF), sex 
hormones and possibly adipokines (see literature review section). The risk of colon cancer 
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may particularly be increased by obesity through the insulin/IGF axis (68), and in women, 
the high levels of oestrogen (sex hormone) associated with increased BMI in post-
menopausal women may produce opposing effects (68, 21). The opposing effects of 
oestrogens and the insulin/IGF axis may about balance or offset each other and 
consequently resulting into little or no substantial association left between BMI and colon 
cancer risk as seen in older or post-menopausal women (68). This may speculatively account 
for the negative, albeit not statistically significant association we observed in the older 
women in our study. In the pre-menopausal women, obesity tends to increase insulin level 
but it is a negligible means of oestrogen (due to higher ovarian production). Hence, the 
adverse effects of the high level of insulin may hold sway (68). This may speculatively 
explain the increased BMI associated with increased colon cancer risk in the pre-
menopausal women observed in our study. 
If these submissions are apposite, it further means that increased BMI would remain a risk 
factor in post-menopausal women on oestrogens replacement therapy (68), even if 
oestrogen replacement therapy by itself may reduce colon cancer risk (73). 
The public health relevance of these findings further underscores the importance of keeping 
healthy body weight in men, young women, and probably as well as in older women on 
oestrogen replacement therapy. 
5.5 Cancer of the Rectum, Recto-sigmoid and Anus 
As mentioned earlier, there were only 3 cases of cancer of the anus in our study, thus, our 
findings basically reflect relationships between BMI and cancer of the rectum and recto-
sigmoid. Our results suggest that increase BMI is associated with increased risk of this type 
of cancers. This is observed in both men and women, but is slightly stronger in men than in 
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women. However, the observed associations are neither statistical significant in men nor 
women (Table 14). Unlike in colon cancer, menopausal status appeared to have no effect 
modification on the risk of rectal and recto-sigmoid cancers. 
The positive association between obesity and the risk of rectal and recto-sigmoid cancers 
was also found in similar other studies. Some studies reported that the association was 
stronger in men than in women (74, 75), while others reported it was limited to only men 
(76-78), and some found no association in both genders (79). 
The tentative biological mechanism involving insulin, IGF, sex hormones and adipokines 
earlier expounded in respect of colon cancer may also be tenable for the relationship 
observed here. Furtherance to that, that increased BMI and cancer risk is stronger for colon 
than rectal cancer may mean that these or other mechanisms related to obesity are 
stronger for colon than for rectal cancer (78), and several studies have reported that the 
level of C-peptide and leptin (an adipokine) were more strongly and positively associated 
with risk of colon cancer than rectal cancer (78). 
5.6 Colorectal Cancers 
Our results suggest that increase BMI is associated with increased risk of colorectal cancers 
in men, whereas there are no substantial changes in the risk in women, except a relatively 
small (but statistically not significant) increased risk in the obese (Table 16 and Figure 11). 
The findings were grossly similar to what were observed in the BMI-colon cancer 
relationship, especially in men.  
The relatively small increased risk in obese women becomes more profound when the 
analyses are limited to women less than 36 years old at baseline.  Moreover, the linear 
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relationship between BMI and the risk of colorectal cancer in the women less than 36 years 
in age, though not statistically significant, may also indicate the possible modifying effect of 
the menopausal status in women regarding the risk of colorectal cancer, or may actually be 
a reflection of the colon cancers present in the analyses. 
Meta-analyses have indicated that BMI may be more strongly associated with colon cancer 
than rectal (81, 82) cancer incidence. Our findings were consistent with previous studies 
where stronger positive relationship for BMI and colorectal cancer risk were found in men 
compared to women (83, 84). When we restricted the analyses in women to those aged 36 
years and below, our results were similar to that of Terry et al (2001) conducted in Sweden 
(72). 
The biological mechanism by which increased BMI increases colorectal cancer risks are 
largely unclear (71), but the speculative explanations previous provided under colon cancer 
may equally be accountable here. In addition, the possible mechanism(s) for gender 
difference is thought to be probably related to testosterone concentration. Studies have 
shown that increased BMI is inversely related to testosterone concentration in men (39) 
while it is directly related in women (80). Therefore, a reduction in testosterone 
concentration caused by obesity may be one reason for stronger association of increased 
BMI with colon and rectal cancer risk in men than in women (78). However, as recently 
argued by Kitachara et al (2013), additional studies are needed for better understanding of 
the biologic mechanism(s) underpinning these associations (71). 
Our findings further highlighted the importance of early adulthood weight control in both 
men and women. 
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5.7 Limitations and Strengths of the Study 
We need to acknowledge some limitations in this study. Some invited participants within 
the stipulated birth cohorts did not attend Tromsø 3 survey; we do not have knowledge of 
the BMI of these non-attendees. Even though the participants were at liberty to attend at 
suitable time within the timeframe of about a year, non-attendees were 25 per cent of the 
total invitees. This estimate is lower (approximately 20 per cent) if people who gave reasons 
for not attending are taken in to consideration (19). This may be a possible source of 
selection bias in the study. However, Montgomery et al (2010) posited in their study that 
the differences between participants and non-participants in prospective cohort study are 
generally small, and they did not find significant evidence of selection bias (85). In another 
study by Knudsen et al (2010), they also opined that non-participation in the study of 
association between exposure and outcome may not have any serious threat to the validity 
of the results (86). Thus, we do not consider that the 25 per cent non-attendees in Tromsø 3 
survey would have introduced any substantial selection bias into our results. Moreover, 
prospective studies like ours, where the outcome is unknown at the time of enrolment are 
less susceptible to selection bias (87). 
BMI is a surrogate measure of body fat and the measurement relies solely on the weight 
and height. Accordingly, BMI usually overestimates the adipose tissue (body fat) in people 
with more lean body mass, such as muscular people and athletes (88), while it 
underestimates the body fats in people with less lean body mass such as the elderly and 
people having eating disorder like in anorexia nervosa and bulimia nervosa (88). Therefore, 
some group of people who are fit and athletic or body builders could have been 
misclassified as overweight, while some old individuals or in muscle wasting disorders may 
47 
 
have also been misclassified as low weight. This may potentially lead to bias of 
misclassification of exposure (87). There were, however, no elderly (65 years and above) 
and probably very few muscular subjects and patients with eating or muscle wasting 
disorders in the sample. 
Other anthropometric measures reflecting the body fat (such as waist circumference, waist-
to-height ratio, and waist-to-hip ratio) have been suggested and used in some studies. 
Unfortunately we do not have any of these in Tromsø 3 survey either as alternatives or for 
comparison to BMI measurement. Howbeit, studies have shown that BMI correlates 
sufficiently high enough with body fat (89) to minimise misclassification mentioned above, 
and therefore, we do not suppose this could have compromised our results. 
Measurement of BMI close to the time of diagnosis of cancer may be lower than the 
preclinical values, and may also have led to misclassification. To assess the possibility of this 
effect (if any), each BMI-cancer analysis was further verified by excluding cases diagnosed 
within the first 3 or 5 years of the follow-up (as deemed appropriate), and we checked for 
attenuation or complete alteration of the results or patterns previously observed. Our 
results did not suggest that the preclinical disease had any significant impact on our results 
or on the conclusions. 
Changes in BMI after the study began were not factored in in the study. However, even 
though BMI tends to increase with age, and more strongly in relatively young adults than 
older subjects, there is a strong tracking with regards to BMI; the correlation between BMI 
at baseline and after, for instance after 10 years, is high (92). Furthermore, the classification 
with regards to confounders (such as smoking) may have changed during follow-up period. 
These changes may have had effects on the possible outcome of the participants (having 
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incident cancer or not), and some residual confounding is likely. In addition, we did control 
for smoking status in all our analyses, but, we could not assess the contribution of 
environmental tobacco smoke (ETS) exposure in these BMI-cancer relationships. The 
amount of ETS exposure in never-smokers may be essential for ascertaining the cancer risks 
related to ETS exposure (90).  
The possible effects of family history of obesity and cancer were not explored in this study. 
Both obesity and cancer are known to correlate within families (91), but we do not have 
adequate information suitable for analyses for both in our study. Likewise, information on 
dietary intake (such as red or processed meat) was also not available. As BMI and dietary 
habits are linked in different (and sometimes quite complicated) ways, this may be a 
weakness in our study. 
Regardless of the above, our study had the evident strength of a population-based 
prospective design, with a comparatively long follow-up time (1986 to 2010). There was 
relatively high attendance rate (about 75%) and minimal loss to follow-up (19). Baseline 
information including weight and height of participants were collected beforehand, thus 
avoiding the exposure-recall bias which is an integral of case-control studies. The cohorts 
used in the study were based on birth-year and not based on professional affiliation (e.g. 
nurses) or church membership (e.g. Adventist) as in some studies, which could introduce 
possibilities of bias. The study also enjoyed the advantage of measured (not self-reported) 
values of height and weight, and the reliability of the connected Norwegian registries for 
cancer diagnosis, death, and emigration. Thus, body mass index at baseline was measured 
with high validity and the follow-up of deaths and incident cancers with histologic 
confirmations were mostly assured and complete. 
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5.8 External Validity 
The findings in this study may be generalizable to cities similar to Tromsø municipality in 
population homogeneity, and to the rest of Norway, Europe or any similar population that is 
predominantly Caucasian. However, the generalizability may not extend to Asia and Africa 
because, for instance, Asians have more body fat at any given BMI compared to Caucasians 
(93). Increased risks of diabetes and cardiovascular diseases may thus start at lower BMI in 
Asian population compared to Caucasians and this may extend to cancer risks as well (84). 
Therefore, the BMI cut-offs for overweight and obesity may be expected to be different in 
Asians. 
5.9 Recommendation for Future Studies 
Obesity-related cancers are diverse and there still exist much knowledge gaps in the 
mechanism(s) underpinning the association between obesity and cancers, and what is 
actually responsible for the gender difference observed in some cancer incidents. More 
studies are still required in this area for better understanding. A better understanding may 
lead to improved or development of new public health approach to the prevention and 
treatment of BMI-related cancers. 
It has also been implied that waist circumference, waist-hip-ratio and waist-to-height ratio 
(as measure of obesity) may be better predictors of future health risk than BMI (94). 
However, there is need for big cohort studies to evaluate these measures alongside BMI as 


























CHAPTER 6: CONCLUSION 
The purpose of this current study was to determine the relationship between BMI and the 
total cancer incidence as well as its relationships with some common specific cancers. This 
was done in relatively young subjects (in cancer research perspective). 
The findings demonstrated that both the underweight and obese men were at increased risk 
of total incident cancer while the women were not. Thus, our first hypothesis that low and 
high BMIs increase the risk of total incident cancers holds in men but not in women. For 
specific cancers, adiposity may be a threat to the men as regards colon and colorectal 
cancers, and similarly to the relatively young premenopausal women, but not to the older 
women. Low weight and obese subjects may be at increased risk of lung cancer, whereas 
prostate cancer appeared to be indifferent to adiposity. Thus, our second hypothesis that 
low and high BMIs increase the risks of common cancers is gender specific and holds for 
some specific cancers (such as lungs and colon), but fell for others (such as prostate). 
Our findings confirmed previous studies and contributed additional evidence in respect of 
BMI and total incident cancer risk, colon and colorectal cancer risks, and the possible 
modifying effect of menopausal status in the risk of colon cancer in women. Our study also 
supported the existing knowledge that underweight individuals who smoke may be at 
higher risk of lung cancer. 
These results suggested that the safest body weight in respect of reducing ones cancer risks 
may be the “normal” weight, as both ends of the BMI spectrum may be at increased risk of 
future cancer development. Therefore, public health policies directed at reducing incidence 



























1. Barness LA, Opitz JM, Gilbert-Barness E. Obesity: Genetic, molecular, and environmental 
aspects. Am J of Med Genet. 2007;143A:3016-34. 
2. World Health Organization [Internet]. Obesity and overweight. [Updated 2014 May; cited 
2014 Jun 24]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ 
3. Farlex Partner Medical Dictionary [Internet] Obesity. [Cited 2014 Jun 24]. Available from: 
http://medical-dictionary.thefreedictionary.com/obesity 
4. Centre for Disease Control and Prevention. [Internet]. Healthy Weight: Causes of 
Overweight and Obesity - other factors in weight gain. [Updated 2011 Sept 13; cited 2014 
Jul 5]. Available from: http://www.cdc.gov/healthyweight/calories/other_factors.html 
5. Pollack A. AMA recognizes obesity as a disease. The New York Times [Internet] 2013 Jun 18 
[cited 2014 Mar 5]. Available from: http://www.nytimes.com/2013/06/19/business/ama-
recognizes-obesity-as-a-disease.html 
6. Hjartåker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer 
repercussions. Adv Exp Med Biol. 2008;630:72-93. 
7. World Cancer Research Fund International [Internet]. European Congress on Obesity [cited 
2014 May 22]. Available from: http://www.wcrf.org/conferences/conference.php?ID=2 
8. National Cancer Institute [Internet]. Obesity and Cancer Risk. [Updated 2012 Mar 01; cited 
2013 May 22]. Available from:  http://www.cancer.gov/cancertopics/factsheet/Risk/obesity. 
9. Jacobsen B, Njølstad I, Thune I, Wilsgaard T, Løchen M, Schirmer H. Increase in weight in all 
birth cohorts in a general population: The Tromsø Study, 1974-1994. Arch Intern Med. 
2001;161:466-72. 
10. Midthjell K, Lee CMY, Langhammer A, Krokstad S, Holmen TL, Hveem K, et al. Trends in 
overweight and obesity over 22 years in a large adult population: the HUNT Study, Norway. 
Clinical Obesity. 2013;3:12-20. 
11. Aars NA. A longitudinal study of the changes in BMI, waist circumference, waist-to-height 
ratio and desired BMI of the participants in the 4th, 5th and 6th survey of the Tromsø study. 
Unpublished master thesis. UiT The Arctic University of Norway; 2014. 
12. World Health Organization. [Internet]. Cancer. [Updated 2014 Feb; cited 2014 Mar 6]. 
Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ 
54 
 
13. International Agency for Research on Cancer. [Internet]. Globocan 2012: Estimated Cancer 
Incidence, Mortality and Prevalence Worldwide in 2012 [cited 2014 Mar 6]. Available from: 
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx 
14. Brook D. Does being obese cause colon cancer? [Updated 2013 March 13; cited 2013 
October 20] Available from: 
http://www.cancer.org/cancer/news/expertvoices/post/2013/03/13/does-being-obese-
cause-colon-cancer.aspx. 
15. Brown P, Allen A. Obesity linked to some forms of cancer. W V Med J. 2002;98:271-2. 
16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, Obesity, and Mortality 
from Cancer in a Prospectively Studied Cohort of U.S. Adults. N Engl J of Med. 
2003;348:1625-38.  
17. Odegaard AO, Koh WP, Yu MC, Yuan JM. Body mass index and risk of colorectal cancer in 
Chinese Singaporeans. Cancer. 2011;117:3841-9.  
18. Koh W-P, Yuan J-M, Wang R, Lee H-P, Yu MC. Body mass index and smoking-related lung 
cancer risk in the Singapore Chinese Health Study. Br J Cancer. 2010;102:610-4. 
19. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: the Tromso 
Study. Int J Epidemiol. 2012;41:961-7. 
20. History of obesity [Internet]. [Cited 2014 Mar 24]. Available from: http://www.dawn-
centre.ie/index.php?page=Page&op=show&id=90 
21. Haslam DW, James WPT. Obesity. The Lancet. 2005;366:1197-209. 
22. Williams SCP. Link between obesity and cancer. PNAS. 2013;110:8753-4. 
23. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass 
index to tumor markers and survival among young women with invasive ductal breast 
carcinoma. Cancer. 2001;92:720–9.  
24. Bergström A, Pisani P, Tenet V, Wolk A, Adami H-O. Overweight as an avoidable cause of 
cancer in Europe. International Journal of Cancer. 2001;91:421–30. 
25. Ceschia M, Gutzwillerb F, Mochc H, Eichholzerb M, Probst-Henscha NM. Epidemiology and 
pathophysiology of obesity as a cause of cancer. Swiss Med Wkly. 2007;137:50-6 
26. Wolin KY, Carson K, Colditz GA. Obesity and Cancer. Oncologist. 2010;15:556-65. 
27. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed 
mechanisms. Nature Reviews Cancer. 2004;4:579–91.  
55 
 
28. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of 
cancer: a systematic review and meta-analysis of prospective observational studies. The 
Lancet. 2008;371:569–78.  
29. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in 
relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134. 
30. Renehan AG. Epidemiology of Overweight/Obesity and Cancer Risk. In: McTiernan A, editor. 
Physical Activity, Dietary Calorie Restriction, and Cancer [Internet]. Springer New York; 2011 
p. 5–23. [cited 2014 Mar 14]. Available from: http://dx.doi.org/10.1007/978-1-4419-7551-
5_2 
31. De Pergola G, Silvestris F. Obesity as a Major Risk Factor for Cancer. Journal of Obesity. 
2013;2013:1–11.  
32. International Agency for Research on Cancer. Weight control and physical activity In IARC 
Handbook of Cancer Prevention, H. Vainio and F. Bianchini, Eds., vol. 6, pp. 1-315, IARC 
Press, Lyon, France, 2002. 
33. Basen-Engquist K, Chang M. Obesity and Cancer Risk: Recent Review and Evidence. Curr 
Oncol Rep. 2011;13:71–6.  
34. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological 
mechanisms. Arch Physiol Biochem. 2008;114:71–83.  
35. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 
2003; 35:694–704. 
36. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. 
Trends Endocrinol Metab. 2006;17:328–336. 
37. Ma J, Pollak M N, Giovannucci E, Chan J M, Tao Y, Hennekens C H, Stampfer M J. Prospective 
study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I 
and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620–625. 
38. Chan J M, Stampfer M J, Giovannucci E, Gann P H, Ma J, Wilkinson P, Hennekens C H, Pollak 
M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 
1998;279:563-566. 
39. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist 
circumference and waist to hip ratio and change in sex steroid hormones: the 
Massachusetts Male Ageing Study. Clinical Endocrinology. 2006;65:125-31.  
56 
 
40. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, et al. Serum sex steroids in 
premenopausal women and breast cancer risk within the European Prospective 
Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2005;97:755-65. 
41. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, et al. Leptin Enhances, via 
AP-1, Expression of Aromatase in the MCF-7 Cell Line. J Biol Chem. 2003;278:28668–76.  
42. Mizoue T, Tokunaga S, Kasai H, Kawai K, Sato M, Kubo T. Body mass index and oxidative DNA 
damage: A longitudinal study. Cancer Science. 2007;98:1254–8. 
43. Boeing H. Obesity and cancer--the update 2013. Best Pract Res Clin Endocrinol Metab. 
2013;27:219–27. 
44. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at 
the Cancer Registry of Norway: An overview of comparability, completeness, validity and 
timeliness. European Journal of Cancer. 2009;45:1218–31. 
45. Inoue M, Sobue T, Tsugane S, JPHC Study Group. Impact of body mass index on the risk of 
total cancer incidence and mortality among middle-aged Japanese: data from a large-scale 
population-based cohort study--the JPHC study. Cancer Causes Control. 2004;15:671–80.  
46. Colon Cancer Alliance [Internet]. Underweight also increased CRC risk [Updated 2011 May 3; 
cited 2014 Apr 24]. Available from: 
www.ccalliance.org/crc_news/articles/underweight_also_at_increased_CRC_risk.html 
47. Chandra RK. Nutrition and the immune system: an introduction. Am J Clin Nutr. 
1997;66:460S–463S.  
48. Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: an 
overview. Am J Clin Nutr. 1997;66:464S–477S.  
49. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk 
of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:557–63. 
50. Freedland SJ, Aronson WJ. Examining the Relationship between Obesity and Prostate 
Cancer. Rev Urol. 2004;6:73–81. 
51. Hsing AW, Deng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Benichou J, et al. Body size and 
prostate cancer: a population-based case-control study in China. Cancer Epidemiol 
Biomarkers Prev. 2000;9:1335–41. 
52. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to 
prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol. 2000;151:541–9. 
57 
 
53. Lee IM, Sesso HD, Paffenbarger RS Jr. A prospective cohort study of physical activity and 
body size in relation to prostate cancer risk (United States). Cancer Causes Control. 
2001;12:187–93.  
54. Engeland A, Tretli S, Bjørge T. Height, body mass index, and prostate cancer: a follow-up of 
950000 Norwegian men. Br J Cancer. 2003;89:1237–42. 
55. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, et al. Body mass index and 
risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003;95:1240–4. 
56. Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long 
polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for 
the (CAG)n-expanded neuronopathies. Hum Mol Genet. 1995;4:523–7. 
57. Kabat GC, Miller AB, Rohan TE. Body mass index and lung cancer risk in women. 
Epidemiology. 2007;18:607–12.  
58. Rauscher GH, Mayne ST, Janerich DT. Relation between body mass index and lung cancer 
risk in men and women never and former smokers. Am J Epidemiol. 2000;152:506–13. 
59. Kark JD, Yaari S, Rasooly I, Goldbourt U. Are lean smokers at increased risk of lung cancer? 
The Israel Civil Servant Cancer Study. Arch Intern Med. 1995;155:2409–16.  
60. Henley SJ, Flanders WD, Manatunga A, Thun MJ. Leanness and lung cancer risk: fact or 
artifact? Epidemiology. 2002;13:268–76. 
61. Mizoue T, Kasai H, Kubo T, Tokunaga S. Leanness, smoking, and enhanced oxidative DNA 
damage. Cancer Epidemiol Biomarkers Prev. 2006;15:582–5. 
62. Loft S, Vistisen K, Ewertz M, Tjønneland A, Overvad K, Poulsen HE. Oxidative DNA damage 
estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender 
and body mass index. Carcinogenesis. 1992;13:2241–7.  
63. Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry CP Jr, Edwards SM. Body size and 
the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord. 
1998;22:178–84.  
64. Nomura A, Heilbrun LK, Stemmermann GN. Body mass index as a predictor of cancer in 
men. J Natl Cancer Inst. 1985;74:319–23.  
65. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of colon and rectal cancer 
among Hawaii Japanese men. Ann Epidemiol. 1996;6:276–82.  
66. Le Marchand L, Wilkens LR, Mi MP. Obesity in youth and middle age and risk of colorectal 
cancer in men. Cancer Causes Control. 1992;3:349–54.  
58 
 
67. Gerhardsson de Verdier M, Hagman U, Steineck G, Rieger A, Norell SE. Diet, body mass and 
colorectal cancer: a case-referent study in Stockholm. Int J Cancer. 1990 Nov 15;46(5):832-8. 
68. Giovannucci E. Obesity, gender, and colon cancer. Gut. 2002;51:147.  
69. Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut. 
2002;51:191–4. 
70. Oxentenko AS, Bardia A, Vierkant RA, Wang AH, Anderson KE, Campbell PT, et al. Body size 
and incident colorectal cancer: a prospective study of older women. Cancer Prev Res (Phila). 
2010;3:1608–20. 
71. Kitahara CM, Berndt SI, de González AB, Coleman HG, Schoen RE, Hayes RB, et al. 
Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in 
the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2013;31:2450-
9.  
72. Terry P, Giovannucci E, Bergkvist L, Holmberg L, Wolk A. Body weight and colorectal cancer 
risk in a cohort of Swedish women: relation varies by age and cancer site. Br J Cancer. 
2001;85:346-9.  
73. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of 
colorectal cancer: a meta-analysis. Obstet Gynecol.1999;93:880-8.  
74. Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary 
lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal 
cancer.Cancer Res. 1997;57:4787–94.  
75. Mao Y, Pan S, Wen SW, Johnson KC, Canadian Cancer Registries Epidemiology Research 
Group. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. Int J 
Cancer. 2003;105:831-7.  
76. De Verdier MG, Hagman U, Steineck G, Rieger Åk, Norell SE. Diet, body mass and colorectal 
cancer: A case-referent study in Stockholm. Int J Cancer. 1990;46:832–8.  
77. Kune GA, Kune S, Watson LF. Body weight and physical activity as predictors of colorectal 
cancer risk. Nutr Cancer. 1990;13:9–17.  
78. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective 
studies. Am J ClinNutr. 2007;86:556–65.  
79. Slattery ML, Caan BJ, Benson J, Murtaugh M. Energy Balance and Rectal Cancer: An 
Evaluation of Energy Intake, Energy Expenditure, and Body Mass Index. Nutrition and 
Cancer. 2003;46:166–71.  
59 
 
80. Bezemer ID, Rinaldi S, Dossus L, Gils CH van, Peeters PHM, Noord PAH van, et al. C-peptide, 
IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within 
the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes 
Control. 2005;16:561–72.  
81. Moghaddam AA, Woodward M, Huxley R. Obesity and Risk of Colorectal Cancer: A Meta-
analysis of 31 Studies with 70,000 Events. Cancer Epidemiol Biomarkers Prev. 
2007;16:2533–47.  
82. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal 
cancer: findings from 56 observational studies. Obesity Reviews. 2010;11:19–30.  
83. Engeland A, Tretli S, Austad G, Bjørge T. Height and body mass index in relation to colorectal 
and gallbladder cancer in two million Norwegian men and women. Cancer Causes Control. 
2005;16:987–96. 
84. Otani T, Iwasaki M, Inoue M. Body Mass Index, Body Height, and Subsequent Risk of 
Colorectal Cancer in Middle-Aged and Elderly Japanese Men and Women: Japan Public 
Health Center-Based Prospective Study. Cancer Causes Control. 2005;16:839–50.  
85. Montgomery M, Kamel F, Hoppin J, Beane-Freeman L, Alavanja M, Sandler D. Characteristics 
of non-participation and potential for selection bias in a prospective cohort study. Am J Ind 
Med. 2010;53:486–96 
86. Knudsen AK, Hotopf M, Skogen JC, Overland S, Mykletun A. The health status of 
nonparticipants in a population-based health study: the Hordal and Health Study. Am J 
Epidemiol. 2010;172:1306–14. 
87. Pannucci CJ, Wilkins EG. Identifying and Avoiding Bias in Research. Plast Reconstr Surg. 
2010;126:619–25.  
88. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, et 
al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J 
Obes. 2008;32:959–66.  
89. De Schutter A, Lavie CJ, Gonzalez J, Milani RV. Body Composition in Coronary Heart Disease: 
How Does Body Mass Index Correlate With Body Fatness? Ochsner J. 2011;11:220-5.  
90. Kagohashi K, Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Body mass index and lung cancer 
risk in never smokers. Radiol Oncol 2006;40:239-44 
60 
 
91. Kerber RA, Slattery ML, Potter JD, Caan BJ, Edwards SL. Risk of colon cancer associated with 
a family history of cancer or colorectal polyps: the diet, activity, and reproduction in colon 
cancer study. Int J Cancer. 1998;78:157–60.  
92. Wilsgaard T, Jacobsen BK, Schirmer H, Thune I, Løchen ML, Njølstad I, et al. Tracking of 
cardiovascular risk factors: the Tromsø study, 1979-1995. Am J Epidemiol. 2001;154:418–26. 
93. Lear SA, Humphries KH, Kohli S, Birmingham CL. The use of BMI and waist circumference as 
surrogates of body fat differs by ethnicity. Obesity (Silver Spring). 2007;15:2817-24. 
94. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains 
obesity-related health risk. Am J Clin Nutr. 2004;79:379–84. 
 
 
